The role of the adapter protein Picalm in the development of Alzheimer's disease is well known. Now, researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), the German Center for Diabetes Research (DZD), ETH Zurich, and…
Prof. Christian Gaebler, an HIV researcher at Charité – Universitätsmedizin Berlin, has a goal: to develop treatments that cure HIV infection in patients or prompt the immune system to keep the virus in check in the long term, even without…
Severe systemic lupus no longer detectable after cancer medication treatment
Misha Kudryashev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. Published in “The EMBO Journal,” the study points to a potentially…
Lucid Genomics, a pioneering Berlin-based startup spin-off from the Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin, raised €1.3 million pre-seed funding round led by Caesar Ventures, with additional support from…
A team in the labs of Holger Gerhardt and Norbert Hübner at the Max Delbrück Center has elucidated how new arteries form, potentially helping to improve therapies aimed at regenerating heart muscle after a heart attack or stroke. The research was…
Zur Mühlen Group (ZMG) is a leader in the meat production sector in Europe, generating several billions of revenue annually from household brands. The product will be the world’s first single-ingredient meat analog. The meat analog will be launched…
Going through medical treatment is often similar to a long journey. The term “patient journey” refers to all the stages along this path – prevention, the emergence of the first symptoms of a disease, recovery, the ongoing management of a chronic…
Strategic innovation for more progress in gene and cell therapy
So far, research across medical health institutions has been complicated in Germany – not least because it was difficult to obtain relevant and comparable data. In the future, things will get easier for researchers. Of late, they have been able to…
